Brief: Shenzhen Hepalink Pharmaceutical's 2021 Net Profit Down 76.5% Y/Y
11/04/2022 15:04
April 11 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* SAYS 2021 NET PROFIT DOWN 76.5% Y/Y AT 240.8 MILLION YUAN
($37.83 million)
Source text http://www.szse.cn/disclosure/listed/bulletinDetail/index.html?c7e61208-df04-4224-aac3-5a6ff0f7e21e
Further company coverage: 002399.SZ
($1 = 6.3648 Chinese yuan renminbi)
(Reporting by Hong Kong newsroom)
((Ella.Cao@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA